MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism

MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism

Blog Article

Abstract Background Acute pulmonary embolism (APE) remains a diagnostic challenge due to a variable clinical presentation and the lack of a reliable screening tool.MicroRNAs (miRNAs) regulate gene expression in a wide range of pathophysiologic processes.Circulating miRNAs are emerging biomarkers in heart failure, type 2 diabetes and other disease states; however, using plasma miRNAs as biomarkers for the diagnosis of APE is still unknown.

Methods Thirty-two APE patients, 32 healthy controls, and 22 bee by bonnie and neil non-APE patients (reported dyspnea, chest pain, or cough) were enrolled in this study.The TaqMan miRNA microarray was used to identify dysregulated miRNAs in the plasma of APE patients.The TaqMan-based miRNA quantitative real-time reverse transcription polymerase chain reactions were used to validate the dysregulated miRNAs.

The receiver-operator characteristic (ROC) curve analysis was conducted to evaluate the diagnostic accuracy of the miRNA identified as the candidate biomarker.Results Plasma miRNA-134 (miR-134) level was significantly higher in the APE patients than in the healthy controls or non-APE patients.The ROC curve showed that plasma miR-134 was a specific diagnostic predictor of APE with an area under the curve of 0.

833 (95% confidence interval, 0.737 to 0.929; P Conclusions Our findings indicated that plasma miR-134 could be an important trufit wrist brace biomarker for the diagnosis of APE.

Because of this finding, large-scale investigations are urgently needed to pave the way from basic research to clinical utilization.